BlossomHill Therapeutics (NASDAQ:BLSM) Reaches New 52-Week High – Here’s Why

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM)’s stock price reached a new 52-week high on Tuesday . The stock traded as high as $23.38 and last traded at $22.40, with a volume of 13695 shares changing hands. The stock had previously closed at $21.74.

Key Headlines Impacting BlossomHill Therapeutics

Here are the key news stories impacting BlossomHill Therapeutics this week:

• Positive Sentiment: Promising efficacy in lung cancer trial: In the Phase 1/2 SOLARA trial, BH-30643 produced a 45% objective response rate and an 88% disease-control rate among 40 patients with EGFR C797S-positive non-small cell lung cancer (NSCLC), including patients who had received prior EGFR inhibitors. This is a particularly significant opportunity because there are currently no approved targeted therapies for this resistance mutation. BlossomHill Therapeutics SOLARA trial update
• Positive Sentiment: Safety and durability supported the update: Sixty-three percent of patients remained on treatment after a median follow-up of 6.9 months. Among 174 patients treated at expansion doses, treatment-related dose reductions occurred in 9% and discontinuations in 3%, while most EGFR wild-type-related adverse events were Grade 1. Business Insider trial data report
• Positive Sentiment: Regulatory and development catalysts: BH-30643 recently received FDA Fast Track designation, and BlossomHill plans to begin a global Phase 2 study in EGFR C797S-positive NSCLC in the first quarter of 2027. RTTNews Fast Track and SOLARA report
• Neutral Sentiment: The findings are preliminary and come from an ongoing, non-randomized early-stage trial. Additional data will be needed to confirm response durability, safety, and the drug’s likelihood of receiving regulatory approval.
• Negative Sentiment: As a clinical-stage biotechnology company with significant losses and ongoing trial expenses, BlossomHill may require additional financing. Future setbacks, dilution, competitive treatments, or weaker clinical results could pressure BLSM.

Analyst Upgrades and Downgrades

BLSM has been the subject of several research reports. HC Wainwright began coverage on shares of BlossomHill Therapeutics in a report on Tuesday, September 1st. They issued a “buy” rating and a $35.00 price objective for the company. Wall Street Zen raised shares of BlossomHill Therapeutics to a “hold” rating in a research note on Saturday, August 15th. Zacks Research upgraded shares of BlossomHill Therapeutics to a “hold” rating in a research report on Wednesday, September 2nd. Guggenheim initiated coverage on shares of BlossomHill Therapeutics in a research note on Tuesday, September 1st. They issued a “buy” rating and a $30.00 price target for the company. Finally, Lifesci Capital initiated coverage on shares of BlossomHill Therapeutics in a report on Tuesday, September 1st. They issued an “outperform” rating and a $32.00 price objective for the company. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, BlossomHill Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $32.20.

BlossomHill Therapeutics Stock Performance

Insider Activity

In other BlossomHill Therapeutics news, Director Carl Gordon bought 625,000 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $10,000,000.00. Following the acquisition, the director owned 2,714,279 shares in the company, valued at approximately $43,428,464. This represents a 29.91% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Bihua Chen bought 312,500 shares of BlossomHill Therapeutics stock in a transaction dated Monday, August 10th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $5,000,000.00. Following the completion of the transaction, the director directly owned 3,614,034 shares in the company, valued at approximately $57,824,544. This trade represents a 9.47% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have purchased 1,573,900 shares of company stock worth $25,181,900.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.